For: | An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2449-2462 [PMID: 38994132 DOI: 10.4251/wjgo.v16.i6.2449] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v16/i6/2449.htm |
Number | Citing Articles |
1 |
Fan Yang, Ying Mao, Hanyu Huang, Wen Luo, Li Liu, Wenzhi Chen. The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1579293
|
2 |
Linfeng Liu, Dengzhuo Chen, Liang Wen, Yongli Ma, Jinghui Li, Guosheng Zhang, Hongkai Hu, Chengzhi Huang, Xueqing Yao. Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy 2025; 25(4): 411 doi: 10.1080/14737140.2025.2474736
|
3 |
Leping Kong, Chin Hang Yiu, Christine Y. Lu. Effectiveness and Safety of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review of Real-World Studies. Current Oncology Reports 2025; doi: 10.1007/s11912-025-01676-0
|